Should I Buy OABI? OABI 2026 Analysis

Should You Buy OmniAb Inc (OABI) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion

Hold

Latest Price

1.860

1 Day change

0.54%

52 Week Range

4.020

Analysis Updated At

2026/01/26

OmniAb Inc (OABI) is not a strong buy for a beginner, long-term investor at this moment. While the technical indicators show some bullish signs, the company's financial performance is weak, with significant revenue and EPS declines. Additionally, there are no strong positive catalysts or recent news to support immediate growth. Analysts maintain a Buy rating but have lowered the price target, indicating caution. Given the lack of strong trading signals and the company's financial struggles, holding off on investing in this stock is recommended for now.

Technical Analysis

The MACD is slightly positive but contracting, RSI is neutral at 52.267, and moving averages are bullish (SMA_5 > SMA_20 > SMA_200). Key support and resistance levels are Pivot: 1.963, R1: 2.058, S1: 1.868. Overall, the technical indicators suggest mild bullishness but no strong upward momentum.

Options Data

Bullish

Open Interest Put-Call Ratio

Bullish

Option Volume Put-Call Ratio

The implied volatility is extremely high (IV 30d: 425.15, IV Percentile: 99.6), indicating significant uncertainty. However, the low put-call ratios suggest a lack of bearish sentiment.

Technical Summary

Sell

Buy

Positive Catalysts

Craig-Hallum maintains a Buy rating and highlights positive developments such as the launch of OmniUltra and a growing network of 104 active partners.

Neutral/Negative Catalysts

EPS also declined by -12.50% YoY, and gross margin worsened to -45.47%. There are no recent news or significant insider/hedge fund trading activities.

Financial Performance

In Q3 2025, revenue dropped to $2,239,000 (-46.33% YoY), net income slightly improved to -$16,525,000 (+0.93% YoY), EPS dropped to -0.14 (-12.50% YoY), and gross margin declined significantly to -45.47% (-145.47% YoY). Overall, the financial performance is weak with no clear signs of recovery.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

Craig-Hallum lowered the price target from $10 to $7 but maintains a Buy rating, citing strong business momentum and innovation through OmniUltra and the xPloration Partner Access Program. However, the reduced price target reflects tempered expectations.

6 Analyst Rating

Wall Street analysts forecast OABI stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for OABI is 6.8 USD with a low forecast of 3 USD and a high forecast of 11 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

6 Buy

0 Hold

0 Sell

Strong Buy

Current: 1.850

Low

Averages

6.8

High

Current: 1.850

Low

Averages

6.8

High

Craig-Hallum

Buy

downgrade

$10 -> $7

AI Analysis

2025-11-05

Reason

Craig-Hallum

Price Target

$10 -> $7

AI Analysis

2025-11-05

downgrade

Buy

Reason

Craig-Hallum lowered the firm's price target on OmniAb to $7 from $10 and keeps a Buy rating on the shares. The firm notes the company reported several positive developments this quarter, driven by strong business momentum and a growing network of 104 active partners. Additionally, Craig-Hallum believes that the launch of OmniUltra, following last quarter's introduction of the xPloration Partner Access Program, should facilitate the development of new classes of biologically derived peptide therapeutics and this innovation will drive further partnerships.

RBC Capital

Conor McNamara

Buy

Maintains

$7 → $4

2025-03-27

Reason

RBC Capital

Conor McNamara

Price Target

$7 → $4

2025-03-27

Maintains

Buy

Reason

RBC Capital lowered the firm's price target on OmniAb to $4 from $7 and keeps an Outperform rating on the shares. The company provided lower than expected FY25 revenue guidance, though the outlook is prudent and de-risks lumpy contributions due to its partner's program progression, the analyst tells investors in a research note. RBC adds that its takeaways from OmniAb Q4 include continued program growth with healthy end markets and its view that FY25 revenue guide is achievable with lower cash spend.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for OABI

Unlock Now

OABI Should I Buy

OABI Should I Buy

Should You Buy OmniAb Inc (OABI) Today? Analysis, Price Targets, and 2026 Outlook.

Technical Analysis

Options Data

Technical Summary

Positive Catalysts

Neutral/Negative Catalysts

Financial Performance

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

People Also Watch